Handelsavisen
prelaunch
Companies Healthcare VFY.AX
VF
VFY.AX ASX Advanced Medical Equipment & Technology

Vfy.Ax

A$3,50
Open in Charts → Attach watcher ⌖
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
165,4M AUD
P/E
EV / Rev
Div yield
Op margin
-22 314,6 %
ROE
-113,7 %
Net margin
-50 238,8 %
Debt / equity
0,01
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

VFY.AX operates in the Advanced Medical Equipment & Technology industry, providing specialized healthcare services and equipment.

Business. VFY.AX operates in the Advanced Medical Equipment & Technology industry, providing specialized healthcare services and equipment.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target2,75

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
2,75
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
2 analysts · indicative
Ownership
not yet wired
Profitability
-113,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning VFY.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to VFY.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    VFY.AX operates in the Advanced Medical Equipment & Technology industry, providing specialized healthcare services and equipment.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a high price-to-book ratio of 5.75 and a price-to-tangible-book ratio of 5.75, indicating that the market is valuing the company's equity at a premium relative to its book value. The debt-to-equity ratio is 0.01, suggesting a low level of leverage. However, the company has negative operating and free cash flows, with operating cash flow at -8,801,180 AUD and free cash flow at -32,558,240 AUD, which may raise concerns about its ability to fund operations and growth without external financing.

    Profitability metrics show that the company is currently unprofitable, with a return on equity of -1.1371 and a return on assets of -1.0272. These negative returns indicate that the company is not generating sufficient returns to cover its cost of capital. The operating income is -14,529,050 AUD, and the net income is -32,710,470 AUD, both of which are significantly below the industry median for profitability metrics.

    The company's revenue is concentrated in a single segment, as there are no disclosed segments in the financial data. Geographically, the company's exposure is not specified in the provided data, but the negative operating and free cash flows suggest that the company may be facing challenges in generating consistent revenue across different regions.

    The company's growth trajectory is uncertain, as the provided data does not include specific outlook figures for the current or next fiscal year. However, the negative operating and free cash flows indicate that the company may be struggling to grow its revenue and improve its financial performance. The company's capital expenditure is minimal at -1,850 AUD, suggesting that it is not investing heavily in new projects or expansion.

    The company faces several risk factors, including liquidity concerns due to negative net cash after subtracting total debt. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative operating and free cash flows may necessitate additional financing, which could lead to dilution of existing shareholders' equity. The risk assessment also highlights the potential for dilution, although the probability is currently low.

    Recent events and filings do not provide specific details about the company's operations or financial performance. The company's financial snapshot indicates significant losses and negative cash flows, which may be a cause for concern among investors and analysts. The analyst estimates suggest a mean price target of 2.75 AUD, with a median price target of 2.75 AUD, indicating a slightly positive outlook despite the company's current financial challenges.

    Key takeaways
    • The company has a high price-to-book ratio, indicating that the market is valuing its equity at a premium relative to its book value.
    • The company is currently unprofitable, with negative returns on equity and assets.
    • The company's revenue is concentrated in a single segment, and its geographic exposure is not specified.
    • The company's growth trajectory is uncertain, with negative operating and free cash flows.
    • The company faces liquidity concerns due to negative net cash after subtracting total debt.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    A$3,50
    Market cap
    A$165.4M
    Enterprise value
    A$165.8M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    5.8x
    P / Tangible book
    5.8x
    Tangible book
    A$28.8M
    Net cash
    -A$392.4k
    Current ratio
    11.5
    Debt / equity
    0.0
    ROA
    -1.0%
    ROE
    -1.1%
    Cash conversion
    27.0%
    CapEx / revenue
    -2.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,24
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-10 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,24
    Revenueno estimateno estimate1,8M AUD
    Operating incomeno estimateno estimate-17,6M AUD
    Full-year consensus mean (period as reported by source) · consensus in AUD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy1
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price targetA$2,75 · Median A$2,75
    Low A$2,50High A$3,00
    Operating income · consensus-17,6M AUD
    EPS surprise
    −6,1 %
    reported vs consensus · miss
    Revenue surprise
    −96,5 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowA$2,50
    MeanA$2,75
    MedianA$2,75
    HighA$3,00
    SpotA$3,50
    −21.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-22 314,6 %Bottom quartile
    Net Margin-50 238,8 %Bottom quartile
    ROE-113,7 %Bottom quartile
    Capex / Rev-2,8 %Above median
    D/E0,01Above median
    Cash Conv0,27Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • VFY.AX Market data — financials · 2026-05-29
    • Vitrafy Life Sciences Ltd Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    VFY.AXCanonical
    ASX · AUD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage